Ozempic and Wegovy, the GLP-1 drugs that have taken the world by storm, are now at the center of a growing controversy. While they promise a fresh start and a new body, the reality for some users is a harrowing tale of unexpected consequences. More than 4,000 Americans have filed lawsuits against the manufacturers of these drugs, claiming they were not adequately warned about the life-altering conditions they now face. These side effects, including vision loss and sudden death, have left users feeling betrayed and vulnerable.
One of the most alarming cases involves Diane Wirth, a 66-year-old nurse practitioner who woke up one morning to find she was blind in her right eye. She had started taking Wegovy for weight loss after being bombarded by persuasive ads and success stories. Wirth had tried numerous diets in the past, but nothing seemed to work. The drug was available through her employer's prescription plan at a monthly cost of $35, making it the only option for weight loss.
Wirth's experience is not an isolated incident. Todd Engel, a 63-year-old from Howard County, Maryland, also lost vision in his right eye on New Year's Eve after starting Ozempic for type-2 diabetes. His eyesight went in his left eye 10 months later. The thought of losing his other eye fills him with anxiety, and he now struggles with the little things people take for granted, like meal prep and reading.
The lawsuits against Novo Nordisk, the manufacturer of Ozempic and Wegovy, highlight a deeper issue. The company has been reprimanded by the Food and Drug Administration for failing to report potential side effects. The European Medicines Agency had previously warned of the risk of NAION, a rare condition that can cause permanent vision loss, but the U.S. labels only mentioned vision changes without specifying NAION.
The case of Tracy Ettinghoff's wife, Marsha, is another tragic example. Marsha started taking Ozempic to lose weight for her son's wedding, but six months later, she fell gravely ill and died suddenly. The medical examiner noted pulmonary aspiration as the immediate cause of death, but Ettinghoff's attorneys believe it was caused by an ileus or non-mechanical bowel obstruction, both linked to the drug.
As the GLP-1 market continues to grow, reaching an estimated $150 billion by 2030, the need for transparency and accountability becomes increasingly crucial. Users must be fully informed about the potential risks, and manufacturers must take responsibility for the well-being of those who trust them with their health. The lawsuits against Novo Nordisk are a stark reminder that the pursuit of a new body comes with unforeseen consequences, and the public must be aware of the potential dangers.
